Cel Sci Corporation (CVM)

[lightrock]

@GD

I'm not exactly sure of the comparison here.

Look at the inclusion/exclusion criteria
https://clinicaltrials.gov/ct2/show/NCT01265849?term=multikine&draw=2&rank=3

So apparently we did not exclude what we thought didn't work in PII ?

Meanwhile, in order to hit 298 when we did, the efficacy in the "subgroup" has to be rather dramatic if it is more or less 50% of the test group.

It won't be like NWBO because, I think, the signal is much stronger. If this pans out like this then we did not extend life a little bit in the subgroup, but a lot, more than Fosco's suggestion there (but for the subgroup)

That might sound like the word "cure" for those.

...

Then if the "target" can be introduced to the other 50% as per the article about Dendreon and anti-cancer vaccine... that would be next.